Ephedra Label Warning With Limited PDP Statement Recommended By CRN
This article was originally published in The Tan Sheet
Executive Summary
The Council for Responsible Nutrition suggests FDA require a label warning format for ephedrine alkaloid-containing products featuring a limited principal display panel declaration that refers consumers to more information on another part of the label
You may also be interested in...
Ephedra “Black Box” Warning Considered By FDA
FDA is suggesting that a "black box" warning appear on the principal display panel of all ephedrine alkaloid-containing dietary supplements, FDA Commissioner Mark McClellan, MD/PhD, said during a Feb. 28 briefing held in Washington, D.C
Ephedrine Alkaloid Sensitivity Study Urged By Researchers Boozer, Daly
A large, case-control study may be necessary to determine whether some people have unusually high sensitivity to the potential adverse effects of ephedrine alkaloids, researchers say in the May issue of the International Journal of Obesity
Ephedra/AER Causality Link Not Possible - Cantox/CRN
Ephedrine alkaloid adverse event reports recorded in FDA's Special Nutritional Adverse Event Monitoring System do not establish causation between supplements containing the popular weight loss and sports herbal ingredient and reported AEs, according to a report commissioned by the Council for Responsible Nutrition.